Answers are grounded in this paper and cite their sources.
The 2020 American Society of Hematology guidelines suggested the use of blood transfusion therapy after all other measures to decrease the incidence rates of vaso-occlusive pain events have failed.However, unlike regular blood transfusion therapy for primary and secondary stroke prevention, for which the goal is hemoglobin (Hb) S level 30%, no optimal Hb S threshold has been established to attenuate the severe acute vaso-occlusive pain event incidence rate.The goal of achieving a Hb S <30% is based on the strategy for primary and secondary stroke prevention in children with sickle cell anemia via blood transfusion therapy.The American Society of Hematology 2020 guidelines for sickle cell disease 1 suggested the use of blood transfusion therapy for decreasing acute vaso-occlusive pain events only when other methods such as hydroxyurea, L-glutamine, and crizanlizumab have proven unsuccessful.Despite these recommendations, no Hb S percentage goal threshold was established.
No takes yet. Share an insight, caveat, or question.
Mejías et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: